Curis (CRIS) Shares Outstanding (2010 - 2026)
Curis' (CRIS) quarterly Shares Outstanding (Entity) came in at $968174.0 in Q1 2026, up 127.97% YoY from $424694.0 in Q1 2025, and up 49.77% on a QoQ basis from $646443.0 in Q4 2025.
Curis (CRIS) Shares Outstanding (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Shares Outstanding (Entity) data on file, last reported at $968174.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 127.97% year-over-year to $968174.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $968174.0 (up 127.97% YoY) and the FY2025 annual result came in at $646443.0, up 105.02% from the prior year.
- Shares Outstanding (Entity) rose to $968174.0 in Q1 2026, from $646443.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $968174.0 in Q1 2026 to a low of $229113.0 in Q1 2022.
- A 5-year average of $378688.9 and a median of $294704.0 in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 0.12% — and 2026, when it jumped 127.97%.
- Tracing CRIS's Shares Outstanding (Entity) over 5 years: stood at $241519.0 in 2022, then advanced by 22.02% to $294704.0 in 2023, then advanced by 6.99% to $315314.0 in 2024, then surged by 105.02% to $646443.0 in 2025, then surged by 49.77% to $968174.0 in 2026.
- The last three Shares Outstanding (Entity) figures came in at $968174.0 (Q1 2026), $646443.0 (Q4 2025), and $636693.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | 2.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 968,174.00 |
| Dec 31, 2025 | 658,202.00 |
| Sep 30, 2025 | 784,009.00 |
| Jun 30, 2025 | 631,382.00 |
| Mar 31, 2025 | 424,694.00 |
| Dec 31, 2024 | 315,314.00 |
| Sep 30, 2024 | 297,046.00 |
| Jun 30, 2024 | 290,921.00 |
| Mar 31, 2024 | 289,179.00 |
| Dec 31, 2023 | 264,665.00 |
| Sep 30, 2023 | 286,039.00 |
| Jun 30, 2023 | 241,715.00 |
| Mar 31, 2023 | 241,534.00 |
| Dec 31, 2022 | 233,481.00 |
| Sep 30, 2022 | 234,478.00 |
| Jun 30, 2022 | 229,127.00 |
| Mar 31, 2022 | 229,113.00 |
| Dec 31, 2021 | 228,923.00 |
| Sep 30, 2021 | 229,003.00 |
| Jun 30, 2021 | 228,868.00 |